Nuclea Energy Enters Definitive Business Combination Agreement with Mangoceuticals, Establishing a Path to a Nasdaq Public Listing to Advance the Morpheus Microreactor
Mangoceuticals (MGRX) entered into a definitive business combination agreement with Nuclea Energy, a developer of lead-cooled microreactors, in a transaction that will leave Nuclea shareholders with approximately 96% ownership of the combined company. The deal marks a pivot from men's health telemedicine to advanced nuclear power, targeting the growing demand for carbon-free electricity from AI data centers and remote sites.
Key figures
- Nasdaq cap
- 19.99%
- Refueling cycle
- up to five years
- Nuclea ownership
- 96%
- Reactor output capacity
- 3.5 MWe to 50 MWe
- Directors appointed by nuclea
- 3
- Mgrx existing shareholder ownership
- 4%
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.